Cargando…

Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment

INTRODUCTION: Since the beginning of the pandemic in 2020, COVID-19 has changed the medical landscape. International recommendations for localized prostate cancer (PCa) include deferred treatment and adjusted therapeutic routines. MATERIALS AND METHODS: To longitudinally evaluate changes in PCa trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Harke, Nina N., Wagner, Christian, Hermann, Robert M., Hadaschik, Boris A., Radtke, Jan Philipp, Altay-Langguth, Alev, Aufderklamm, Stefan, Bach, Christian, Becker-Schiebe, Martina, Blana, Andreas, Bruns, Frank, Buse, Stephan, Combs, Stephanie E., Engels, Christina L., Ezzibdeh, Emad, Fiedler, Marcel, Fischer, Laura-Anna, Farzat, Mahmoud, Frismann, Alexander, Heck, Matthias M., Henkenberens, Christoph, Roesch, Marie C., Käding, Christoph, Klautke, Gunther, Krausewitz, Philipp, Kuczyk, Markus A., Leitsmann, Conrad, Lettmaier, Sebastian, Mahjoub, Samy, Manseck, Andreas, Medenwald, Daniel, Meyer, Andreas, Micke, Oliver, Moritz, Rudolf, Ott, Marcel, Peters, Inga, Pokupic, Sasa, Porres, Daniel, Preisser, Felix, Reichel, Kathrin, Schneider, Andreas, Schwentner, Christian, Scobioala, Sergiu, Truss, Michael, Wegener, Daniel, Wezel, Felix, Willborn, Kay, Witt, Jörn H., Wittig, Andrea, Wittlinger, Michael, Wolff, Hendrik A., Zimmermanns, Volker, Christiansen, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197019/
https://www.ncbi.nlm.nih.gov/pubmed/35700180
http://dx.doi.org/10.1371/journal.pone.0269827
_version_ 1784727310595784704
author Harke, Nina N.
Wagner, Christian
Hermann, Robert M.
Hadaschik, Boris A.
Radtke, Jan Philipp
Altay-Langguth, Alev
Aufderklamm, Stefan
Bach, Christian
Becker-Schiebe, Martina
Blana, Andreas
Bruns, Frank
Buse, Stephan
Combs, Stephanie E.
Engels, Christina L.
Ezzibdeh, Emad
Fiedler, Marcel
Fischer, Laura-Anna
Farzat, Mahmoud
Frismann, Alexander
Heck, Matthias M.
Henkenberens, Christoph
Roesch, Marie C.
Käding, Christoph
Klautke, Gunther
Krausewitz, Philipp
Kuczyk, Markus A.
Leitsmann, Conrad
Lettmaier, Sebastian
Mahjoub, Samy
Manseck, Andreas
Medenwald, Daniel
Meyer, Andreas
Micke, Oliver
Moritz, Rudolf
Ott, Marcel
Peters, Inga
Pokupic, Sasa
Porres, Daniel
Preisser, Felix
Reichel, Kathrin
Schneider, Andreas
Schwentner, Christian
Scobioala, Sergiu
Truss, Michael
Wegener, Daniel
Wezel, Felix
Willborn, Kay
Witt, Jörn H.
Wittig, Andrea
Wittlinger, Michael
Wolff, Hendrik A.
Zimmermanns, Volker
Christiansen, Hans
author_facet Harke, Nina N.
Wagner, Christian
Hermann, Robert M.
Hadaschik, Boris A.
Radtke, Jan Philipp
Altay-Langguth, Alev
Aufderklamm, Stefan
Bach, Christian
Becker-Schiebe, Martina
Blana, Andreas
Bruns, Frank
Buse, Stephan
Combs, Stephanie E.
Engels, Christina L.
Ezzibdeh, Emad
Fiedler, Marcel
Fischer, Laura-Anna
Farzat, Mahmoud
Frismann, Alexander
Heck, Matthias M.
Henkenberens, Christoph
Roesch, Marie C.
Käding, Christoph
Klautke, Gunther
Krausewitz, Philipp
Kuczyk, Markus A.
Leitsmann, Conrad
Lettmaier, Sebastian
Mahjoub, Samy
Manseck, Andreas
Medenwald, Daniel
Meyer, Andreas
Micke, Oliver
Moritz, Rudolf
Ott, Marcel
Peters, Inga
Pokupic, Sasa
Porres, Daniel
Preisser, Felix
Reichel, Kathrin
Schneider, Andreas
Schwentner, Christian
Scobioala, Sergiu
Truss, Michael
Wegener, Daniel
Wezel, Felix
Willborn, Kay
Witt, Jörn H.
Wittig, Andrea
Wittlinger, Michael
Wolff, Hendrik A.
Zimmermanns, Volker
Christiansen, Hans
author_sort Harke, Nina N.
collection PubMed
description INTRODUCTION: Since the beginning of the pandemic in 2020, COVID-19 has changed the medical landscape. International recommendations for localized prostate cancer (PCa) include deferred treatment and adjusted therapeutic routines. MATERIALS AND METHODS: To longitudinally evaluate changes in PCa treatment strategies in urological and radiotherapy departments in Germany, a link to a survey was sent to 134 institutions covering two representative baseline weeks prior to the pandemic and 13 weeks from March 2020 to February 2021. The questionnaire captured the numbers of radical prostatectomies, prostate biopsies and case numbers for conventional and hypofractionation radiotherapy. The results were evaluated using descriptive analyses. RESULTS: A total of 35% of the questionnaires were completed. PCa therapy increased by 6% in 2020 compared to 2019. At baseline, a total of 69 radiotherapy series and 164 radical prostatectomies (RPs) were documented. The decrease to 60% during the first wave of COVID-19 particularly affected low-risk PCa. The recovery throughout the summer months was followed by a renewed reduction to 58% at the end of 2020. After a gradual decline to 61% until July 2020, the number of prostate biopsies remained stable (89% to 98%) during the second wave. The use of RP fluctuated after an initial decrease without apparent prioritization of risk groups. Conventional fractionation was used in 66% of patients, followed by moderate hypofractionation (30%) and ultrahypofractionation (4%). One limitation was a potential selection bias of the selected weeks and the low response rate. CONCLUSION: While the diagnosis and therapy of PCa were affected in both waves of the pandemic, the interim increase between the peaks led to a higher total number of patients in 2020 than in 2019. Recommendations regarding prioritization and fractionation routines were implemented heterogeneously, leaving unexplored potential for future pandemic challenges.
format Online
Article
Text
id pubmed-9197019
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-91970192022-06-15 Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment Harke, Nina N. Wagner, Christian Hermann, Robert M. Hadaschik, Boris A. Radtke, Jan Philipp Altay-Langguth, Alev Aufderklamm, Stefan Bach, Christian Becker-Schiebe, Martina Blana, Andreas Bruns, Frank Buse, Stephan Combs, Stephanie E. Engels, Christina L. Ezzibdeh, Emad Fiedler, Marcel Fischer, Laura-Anna Farzat, Mahmoud Frismann, Alexander Heck, Matthias M. Henkenberens, Christoph Roesch, Marie C. Käding, Christoph Klautke, Gunther Krausewitz, Philipp Kuczyk, Markus A. Leitsmann, Conrad Lettmaier, Sebastian Mahjoub, Samy Manseck, Andreas Medenwald, Daniel Meyer, Andreas Micke, Oliver Moritz, Rudolf Ott, Marcel Peters, Inga Pokupic, Sasa Porres, Daniel Preisser, Felix Reichel, Kathrin Schneider, Andreas Schwentner, Christian Scobioala, Sergiu Truss, Michael Wegener, Daniel Wezel, Felix Willborn, Kay Witt, Jörn H. Wittig, Andrea Wittlinger, Michael Wolff, Hendrik A. Zimmermanns, Volker Christiansen, Hans PLoS One Research Article INTRODUCTION: Since the beginning of the pandemic in 2020, COVID-19 has changed the medical landscape. International recommendations for localized prostate cancer (PCa) include deferred treatment and adjusted therapeutic routines. MATERIALS AND METHODS: To longitudinally evaluate changes in PCa treatment strategies in urological and radiotherapy departments in Germany, a link to a survey was sent to 134 institutions covering two representative baseline weeks prior to the pandemic and 13 weeks from March 2020 to February 2021. The questionnaire captured the numbers of radical prostatectomies, prostate biopsies and case numbers for conventional and hypofractionation radiotherapy. The results were evaluated using descriptive analyses. RESULTS: A total of 35% of the questionnaires were completed. PCa therapy increased by 6% in 2020 compared to 2019. At baseline, a total of 69 radiotherapy series and 164 radical prostatectomies (RPs) were documented. The decrease to 60% during the first wave of COVID-19 particularly affected low-risk PCa. The recovery throughout the summer months was followed by a renewed reduction to 58% at the end of 2020. After a gradual decline to 61% until July 2020, the number of prostate biopsies remained stable (89% to 98%) during the second wave. The use of RP fluctuated after an initial decrease without apparent prioritization of risk groups. Conventional fractionation was used in 66% of patients, followed by moderate hypofractionation (30%) and ultrahypofractionation (4%). One limitation was a potential selection bias of the selected weeks and the low response rate. CONCLUSION: While the diagnosis and therapy of PCa were affected in both waves of the pandemic, the interim increase between the peaks led to a higher total number of patients in 2020 than in 2019. Recommendations regarding prioritization and fractionation routines were implemented heterogeneously, leaving unexplored potential for future pandemic challenges. Public Library of Science 2022-06-14 /pmc/articles/PMC9197019/ /pubmed/35700180 http://dx.doi.org/10.1371/journal.pone.0269827 Text en © 2022 Harke et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Harke, Nina N.
Wagner, Christian
Hermann, Robert M.
Hadaschik, Boris A.
Radtke, Jan Philipp
Altay-Langguth, Alev
Aufderklamm, Stefan
Bach, Christian
Becker-Schiebe, Martina
Blana, Andreas
Bruns, Frank
Buse, Stephan
Combs, Stephanie E.
Engels, Christina L.
Ezzibdeh, Emad
Fiedler, Marcel
Fischer, Laura-Anna
Farzat, Mahmoud
Frismann, Alexander
Heck, Matthias M.
Henkenberens, Christoph
Roesch, Marie C.
Käding, Christoph
Klautke, Gunther
Krausewitz, Philipp
Kuczyk, Markus A.
Leitsmann, Conrad
Lettmaier, Sebastian
Mahjoub, Samy
Manseck, Andreas
Medenwald, Daniel
Meyer, Andreas
Micke, Oliver
Moritz, Rudolf
Ott, Marcel
Peters, Inga
Pokupic, Sasa
Porres, Daniel
Preisser, Felix
Reichel, Kathrin
Schneider, Andreas
Schwentner, Christian
Scobioala, Sergiu
Truss, Michael
Wegener, Daniel
Wezel, Felix
Willborn, Kay
Witt, Jörn H.
Wittig, Andrea
Wittlinger, Michael
Wolff, Hendrik A.
Zimmermanns, Volker
Christiansen, Hans
Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment
title Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment
title_full Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment
title_fullStr Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment
title_full_unstemmed Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment
title_short Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment
title_sort lessons learned after one year of covid-19 from a urologist and radiotherapist view: a german survey on prostate cancer diagnosis and treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197019/
https://www.ncbi.nlm.nih.gov/pubmed/35700180
http://dx.doi.org/10.1371/journal.pone.0269827
work_keys_str_mv AT harkeninan lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT wagnerchristian lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT hermannrobertm lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT hadaschikborisa lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT radtkejanphilipp lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT altaylangguthalev lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT aufderklammstefan lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT bachchristian lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT beckerschiebemartina lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT blanaandreas lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT brunsfrank lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT busestephan lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT combsstephaniee lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT engelschristinal lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT ezzibdehemad lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT fiedlermarcel lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT fischerlauraanna lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT farzatmahmoud lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT frismannalexander lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT heckmatthiasm lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT henkenberenschristoph lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT roeschmariec lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT kadingchristoph lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT klautkegunther lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT krausewitzphilipp lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT kuczykmarkusa lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT leitsmannconrad lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT lettmaiersebastian lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT mahjoubsamy lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT manseckandreas lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT medenwalddaniel lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT meyerandreas lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT mickeoliver lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT moritzrudolf lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT ottmarcel lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT petersinga lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT pokupicsasa lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT porresdaniel lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT preisserfelix lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT reichelkathrin lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT schneiderandreas lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT schwentnerchristian lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT scobioalasergiu lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT trussmichael lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT wegenerdaniel lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT wezelfelix lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT willbornkay lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT wittjornh lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT wittigandrea lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT wittlingermichael lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT wolffhendrika lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT zimmermannsvolker lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment
AT christiansenhans lessonslearnedafteroneyearofcovid19fromaurologistandradiotherapistviewagermansurveyonprostatecancerdiagnosisandtreatment